TARSUS PHARMACEUTICALS INC. - COMMON STOCK

Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention

04 May 2021 16:05:01 By Nasdaq GlobeNewswire

Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis

03 May 2021 16:08:25 By Nasdaq GlobeNewswire

Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference

27 Apr 2021 16:05:00 By Nasdaq GlobeNewswire

Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates

31 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease

29 Mar 2021 16:05:00 By Nasdaq GlobeNewswire

Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel

19 Jan 2021 08:30:00 By Nasdaq GlobeNewswire

Tarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources Officer

07 Jan 2021 09:24:29 By Nasdaq GlobeNewswire

Tarsus Pharmaceuticals, Inc. to Present at the 2021 ICR Virtual Conference

05 Jan 2021 17:00:00 By Nasdaq GlobeNewswire